

At a glance:

Clemedi markets an innovative best-in-class platform to diagnose infectious diseases without bacterial culture.

Sector: Medical Diagnostics
Product: CE-IVD certified
Stage: pre-commercialization
Raising: \$ 4M
Closing: Dec '22
Use of funds: build up sales
Exit: trade sale in 5 years

Recent achievements

- CE-IVD mark
- 2 centers enrolled in evaluation study
- Patent filed in 5 main markets for Tuberculini

Next highlights

- Market entry EU
- Market entry India
- Evaluation latent TB

Past funding

- Grants: \$ 1M
- Convert. loans: \$ 0.5M

Founders / Management

- [in Dr. Sebastian Dümcke, CEO](#)
- [in Niko Fischer-Wasels, CFO](#)
- [in Dr. Prajwal, CSO](#)
- [in Prof. Thorsten Buch, Pres.](#)
- [in Dr. Peter Keller, CMA](#)

Board

- [in Jean-Pierre Hermet](#)
- [in Reinhard Stary](#)
- [in Dr. Manuela Schneider-Höfferer](#)

Partners (R&D, Validation & Manufacturing)

- CHUV Lausanne, CH
- IFIK Berne, CH
- University of Zurich
- ESIC, India
- FIND Geneva, CH
- Thyrocare, India
- Biotype, Germany
- ThermoFisher, USA
- ententee, Czech Republic

Clemedi

Disruptive microbial diagnostics




PROBLEM

- 5 mn deaths / year due to antibiotic resistance
- Bacterial culture is time and resource intensive
- Late therapy start reduces success
- Growing resistance is challenging for the selection of right therapy
- Economic damage comparable to 2008/09 financial crisis

SOLUTION

- **Clemedi is a best-in-class platform** to diagnose infectious diseases
- Combines **DNA sequencing & AI**
- Turnaround time: **24-48 h**
- One **unified software interface** for all applications
- Patent application EU, US, ZA, IN, CN

Diagnostic process on our platform has 5 steps and takes 24-48 hours:



1: DNA Extraction 2: Amplification 3: Sequencing 4: AI 5: Diagnostic Report

MARKET

- Total market: \$ 13.3 Bn
- Addressable market: \$ 6.5 Bn
- Market sizes by disease:
 - Active TB: \$ 2.5 Bn
 - Latent TB: \$ 1.8 Bn
 - STI: \$ 9 Bn

USPs

- **Comprehensive:** 190 res. markers
- **Fast:** results in under 48 h
- **Convenient:** sample to result
- **High throughput:** 24 samples/run
- **Add-on:** contact tracing, phylogeny, outbreak detection
- **Unified software** interface across applications

FIRST APPLICATION: TB



- Diagnosis of drug-resistant tuberculosis
- **CE-IVD mark** in the EU
- **12 antibiotics** within **48 hours** versus 4-10 weeks currently
- Target markets: EU and India

APPLICATION PIPELINE



Active tuberculosis: Short time-to-market, strong international support



Latent tuberculosis: extension of previous product, need in high-income countries



Sexually transmitted infections: High resistance rates, large market

GET IN TOUCH!

Clemedi AG
Dr. Sebastian Dümcke
Schlieren, Switzerland

duemcke@clemedi.com
+41 (0)43 229 38 21
clemedi.com